Arcturus Therapeutics (NASDAQ: ARCT) — Perfil da empresa, notícias e dados financeiros
Arcturus Therapeutics develops RNA therapeutics for rare diseases and vaccines, focusing on innovative solutions for unmet medical needs.
Arcturus Therapeutics
Arcturus Therapeutics (NASDAQ:ARCT) is a biotechnology company focused on the discovery, development, and commercialization of RNA therapeutics for rare diseases and vaccines. The company leverages its proprietary lipid nanoparticle delivery system and RNA platforms to develop novel therapeutics. Arcturus’s projects include treatments for cystic fibrosis, liver diseases, and a diverse pipeline of mRNA vaccines against infectious diseases. The objective of Arcturus is to harness the potential of RNA therapies to address unmet medical needs and improve patient outcomes through its innovative research and development efforts.
Resumo
Operações
Produtos e/ou serviços de Arcturus Therapeutics
- LUNAR-COV19 (ARCT-021), a vaccine candidate designed to prevent COVID-19 using self-amplifying mRNA technology.
- LUNAR-OTC, aiming to treat Ornithine Transcarbamylase (OTC) Deficiency by delivering OTC mRNA to liver cells.
- LUNAR-CF, focused on treating Cystic Fibrosis through the delivery of mRNA to the lungs to enable CFTR protein production.
- ARCT-810, an mRNA therapeutic candidate targeting Ornithine Transcarbamylase Deficiency, utilizing LUNAR lipid-mediated delivery to enhance protein expression.
- Preclinical pipeline including various mRNA-based therapeutic and vaccine candidates targeting infectious diseases and rare disorders.
equipe executiva do Arcturus Therapeutics
- Joseph E. PayneFounder, President, CEO & Director
- Padmanabh ChivukulaFounder, Chief Scientific Officer, COO & Secretary
- Joseph RobertsPrincipal Accounting Officer & Controller
- Lance KurataChief Legal Officer
- Dennis M. MulroyChief Financial Officer
- Neda SafarzadehVice President and Head of IR/PR & Marketing
- Natasha O. BowmanChief Human Resources Officer
- Kevin T. SkolChief Business Officer
- Igor SmolenovChief Development Officer
- Ye ZhangChief Regulatory & Quality Assurance Officer
Últimas notícias sobre a Arcturus Therapeutics
Principais indicadores financeiros
Resultados divulgados pela Arcturus Therapeutics, em USD.
- Cap. de mercado
- 332 mi
- Receita (TTM)
- 29,4 mi
- P/L
- —
- LPA (diluído, TTM)
- -3.3
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 67,2 mi | -75 mi | -65,8 mi | |
| 138,4 mi | -95,7 mi | -80,9 mi | |
| 157,7 mi | -78,2 mi | -29,7 mi | |
| 205,8 mi | 12,2 mi | 9,3 mi |